Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.59 |
| ▸ | APP | P05067 | 8/20 | 0.59 |
| ▸ | BCHE | P06276 | 8/20 | 0.59 |
| ▸ | CCNC | P24863 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | TRIM58 | Q8NG06 | 2/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21055798 | 0.88 | LMNA (0.59) | ACHEAPPBCHETRIM58L3MBTL1 | |
| SCHEMBL21055815 | 0.87 | APP (0.59) | ACHEAPPBCHETRIM58SLC2A1 | |
| SCHEMBL21055811 | 0.86 | APP (0.57) | ACHEAPPBCHECCNCCDK8 | |
| SCHEMBL21055812 | 0.85 | APP (0.79) | ACHEAPPBCHESLC2A1KMT2A | |
| SCHEMBL21055806 | 0.84 | GRK6 (0.56) | ACHEAPPBCHETRIM58SLC2A1 | |
| SCHEMBL13283269 | 0.75 | HTT (0.76) | APPCCNCCDK8RXFP1HTT | |
| SCHEMBL16579894 | 0.75 | ACHE (0.58) | ACHEAPPBCHETRIM58KMT2A | |
| SCHEMBL14869419 | 0.74 | APP (0.65) | ACHEAPPBCHESLC2A1L3MBTL1 | |
| SCHEMBL21055791 | 0.74 | TRIM58 (0.74) | ACHEAPPBCHETRIM58KMT2A | |
| SCHEMBL16280680 | 0.74 | BCHE (0.57) | ACHEAPPBCHETRIM58KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323007-B1 | N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323007-B1 | N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof | NQO2, NQO1, NIT2 | ACHE 14/4885APP 742/4885BCHE 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.